What are the best synthetic biology stocks?

The most widely followed synthetic biology stocks in 2026 include Ginkgo Bioworks (NYSE: DNA) -- the largest cell programming platform, Twist Bioscience (NASDAQ: TWST) -- the dominant DNA synthesis company, CRISPR Therapeutics (NASDAQ: CRSP) -- maker of the first approved CRISPR therapy Casgevy, Recursion Pharmaceuticals (NASDAQ: RXRX) -- AI-driven drug discovery, and Beam Therapeutics (NASDAQ: BEAM) -- precision base editing. Illumina (NASDAQ: ILMN) provides infrastructure for the entire sector. There is no single "best" synbio stock -- it depends on your thesis around platform vs. therapeutics, pre-revenue growth vs. established revenue, and risk tolerance.

Is synthetic biology a good investment?

Synthetic biology represents one of the largest addressable markets in deep tech, with McKinsey estimating the bio-based economy could generate $2-4 trillion in annual economic impact by 2030-2040. However, synbio stocks have been extremely volatile. Ginkgo Bioworks went public at a $15B SPAC valuation in 2021 and saw massive compression. Amyris and Zymergen -- once valued at billions -- went bankrupt. The sector rewards patient investors with strong conviction on specific platform theses, but carries significant risk from long development timelines, scaling challenges, and uncertain commercial economics. The strongest performers have been therapeutics companies with approved products (CRISPR Therapeutics) and infrastructure providers (Twist Bioscience, Illumina).

Is Ginkgo Bioworks stock a good buy?

Ginkgo Bioworks (NYSE: DNA) is a polarizing stock in the synbio sector. Bulls point to its unmatched foundry scale, massive codebase of engineered organisms, growing biosecurity division (Concentric), and improving unit economics after restructuring. Bears highlight the continued cash burn, dilutive capital structure from its SPAC merger, competition from AI-native protein design companies, and the challenge of proving platform value across diverse verticals. As of early 2026, Ginkgo has completed a major restructuring and is focused on demonstrating sustainable platform economics. synbiointel.com does not provide investment advice -- this is informational context for research purposes.

Synthetic Biology Stocks: Complete Investor Guide (2026)

Every publicly traded synthetic biology company on US exchanges in 2026. This guide covers 14 actively trading synbio stocks spanning cell programming platforms, gene editing therapeutics, AI drug discovery, biomanufacturing, and infrastructure -- plus cautionary tales from Amyris and Zymergen that every synbio investor should study.

Trading Stocks

Exchanges

NYSE, NASDAQ

Bankrupt / Delisted

Last Updated

Mar 2026

Actively Trading Synbio Stocks14 stocks

Ticker	Company	Exchange	Category	Funding / Valuation	Headcount
DNA	Ginkgo Bioworks	NYSE	Platform	~$1.5B (public market cap, 2025)	1000+
TWST	Twist Bioscience	NASDAQ	Platform	~$2B (public market cap)	800+
ABSI	Absci Corporation	NASDAQ	Platform	~$500M (public market cap)	300+
RXRX	Recursion Pharmaceuticals	NASDAQ	AI Drug Discovery	~$2B (public market cap)	600+
BEAM	Beam Therapeutics	NASDAQ	Gene Editing	~$1.5B (public market cap)	400+
CRBU	Caribou Biosciences	NASDAQ	Gene Editing	~$300M (public market cap)	200+
NTLA	Intellia Therapeutics	NASDAQ	Gene Editing	~$3B (public market cap)	600+
CRSP	CRISPR Therapeutics	NASDAQ	Gene Editing	~$4B (public market cap)	800+
ILMN	Illumina	NASDAQ	Infrastructure	~$20B (public market cap)	8000+
EDIT	Editas Medicine	NASDAQ	Gene Editing	~$500M (public market cap)	300+
VERV	Verve Therapeutics	NASDAQ	Gene Editing	~$800M (public market cap)	200+
SANA	Sana Biotechnology	NASDAQ	Cell Therapy	~$600M (public market cap)	300+
SNTI	Senti Biosciences	NASDAQ	Cell Therapy	~$100M (public market cap)	100+
LNZA	LanzaTech	NASDAQ	Biomanufacturing	~$800M (public market cap)	500+

Cautionary Tales // Bankrupt Synbio Companies

AmyrisAMRS (delisted)Peak: $5B+ market cap

Filed Chapter 11 in August 2023. Burned through $3B+ trying to scale precision fermentation for consumer brands. Failed to achieve cost parity despite 20 years of effort.

Lesson: Vertical integration from fermentation to consumer brands created unsustainable capital requirements.

ZymergenZY (delisted)Peak: $3.4B market cap at IPO

Acquired by Ginkgo Bioworks in 2022 for ~$300M after its flagship product Hyaline failed pre-launch. Stock fell 70% in a single day in August 2021 after revenue guidance withdrawal.

Lesson: Overpromised on product readiness and commercial timeline. Biology risk is real -- lab results do not always translate to production scale.

THE BOTTOM LINE

Synthetic biology stocks in 2026 span 14 publicly traded companies across platforms, therapeutics, and infrastructure. The sector has matured since the 2021 SPAC era -- the bankruptcies of Amyris and Zymergen forced a market-wide reckoning on commercial viability and unit economics.

The strongest public performers have been companies with either approved therapeutic products (CRISPR Therapeutics with Casgevy), essential infrastructure positions (Twist Bioscience in DNA synthesis, Illumina in sequencing), or clear paths to AI-driven drug discovery revenue (Recursion, Absci). Platform companies like Ginkgo Bioworks remain a bet on the horizontal model proving sustainable economics.

For investors, the key lesson from the synbio sector is that biology is not software -- scaling timelines are longer, capital requirements are higher, and unit economics are harder to predict. The winners will be companies that solve the COGS problem (cost of goods at commercial scale) while maintaining technological differentiation. synbiointel.com does not provide investment advice.

Frequently Asked Questions// synthetic biology stocks

RELATED INTELLIGENCE